Pharmaceutical monomers, compositions and uses for the treatment of inflammatory bowel disease
The combination of succinate saponin C, capsicum alkaloid, 4-O-methylpinepic acid and methyl dihydroxydimethylbenzoate provides synergistic treatment for inflammatory bowel disease, overcoming the limitations of existing drug treatments and achieving more effective symptom improvement and enhanced safety.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- HEILONGJIANG UNIV OF CHINESE MEDICINE
- Filing Date
- 2026-04-30
- Publication Date
- 2026-07-17
AI Technical Summary
Existing drugs for treating inflammatory bowel disease lack a radical cure, and commonly used drug treatments are expensive and have significant side effects. Traditional Chinese medicine treatments have limitations, and there are currently no reports on the application of bitter perilla saponin C, succinate, 4-O-methylpinene acid, or methyl dihydroxydimethylbenzoate.
A combination of perilla saponin C, scutellarin, 4-O-methylpinepic acid and methyl dihydroxydimethylbenzoate is used to synergistically treat inflammatory bowel disease by administration via the gastrointestinal tract or non-gastrointestinal route, thereby regulating the intestinal flora, repairing the intestinal barrier, and inhibiting the inflammatory response.
It significantly improves symptoms of inflammatory bowel disease, including weight loss, loose stools, shortened colon, and impaired intestinal barrier; reduces serum levels of pro-inflammatory factors; increases levels of anti-inflammatory factors; and provides a safer and more effective treatment option.
Smart Images
Figure CN122398832A_ABST